(Q37784204)

23 August 2017

title

Escitalopram: a review of its use in the management of major depressive disorder in adults (English)

1 reference

major depressive disorder

23 August 2017

main subject

1 reference

1 reference

1

Karly P Garnock-Jones

1 reference

23 August 2017

Paul L McCormack

2

1 reference

23 August 2017

publication date

1 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

24

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

769-796

1 reference

https://scigraph.springernature.com/pub.10.2165/11204760-000000000-00000

23 August 2017

exact match

0 references

cites work

Australian and New Zealand clinical practice guidelines for the treatment of depression

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11204760-000000000-00000

The burden of depression and anxiety in general medicine.

21 January 2018

1 reference

12 December 2020

Comparison of toxicity of acute overdoses with citalopram and escitalopram

1 reference

12 December 2020

Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial.

1 reference

12 December 2020

Trends in Prescribing of Selective Serotonin Reuptake Inhibitors and Other Newer Antidepressant Agents in Adult Primary Care

1 reference

12 December 2020

Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder

1 reference

12 December 2020

The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects

1 reference

12 December 2020

Escitalopram: a pharmacoeconomic review of its use in depression

1 reference

12 December 2020

Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany

1 reference

12 December 2020

How have the SSRI antidepressants affected suicide risk?

1 reference

12 December 2020

Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial

1 reference

12 December 2020

Antidepressive therapy with escitalopram improves mood, cognitive symptoms, and identity memory for angry faces in elderly depressed patients.

1 reference

12 December 2020

Escitalopram therapy for major depression and anxiety disorders

1 reference

12 December 2020

Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression.

1 reference

12 December 2020

Escitalopram in the long-term treatment of major depressive disorder in elderly patients

1 reference

12 December 2020

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

12 December 2020

Mean platelet volume in patients with major depression: effect of escitalopram treatment.

1 reference

12 December 2020

Escitalopram: a review of its use in the management of major depressive disorder.

1 reference

12 December 2020

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

1 reference

12 December 2020

Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes

1 reference

12 December 2020

Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.

1 reference

12 December 2020

Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients

1 reference

12 December 2020

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.

1 reference

12 December 2020

Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials

1 reference

12 December 2020

In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.

1 reference

12 December 2020

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

1 reference

12 December 2020

Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial.

1 reference

12 December 2020

Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review

1 reference

12 December 2020

Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.

1 reference

12 December 2020

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

12 December 2020

Genetic markers of suicidal ideation emerging during citalopram treatment of major depression

1 reference

12 December 2020

Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study.

1 reference

12 December 2020

Prescription of selective serotonin reuptake inhibitors 1990-2004

1 reference

12 December 2020

Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients

1 reference

12 December 2020

National Patterns of Medication Treatment for Depression, 1987 to 2001

1 reference

12 December 2020

Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans

1 reference

12 December 2020

Escitalopram in the treatment of depressed elderly patients

1 reference

12 December 2020

Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.

1 reference

12 December 2020

A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder

1 reference

12 December 2020

Escitalopram prevents relapse in older patients with major depressive disorder

1 reference

12 December 2020

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.

1 reference

12 December 2020

Superiority of escitalopram to paroxetine in the treatment of depression

1 reference

12 December 2020

Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects.

1 reference

12 December 2020

The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors

1 reference

12 December 2020

Escitalopram in the long-term treatment of major depressive disorder.

1 reference

12 December 2020

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

1 reference

12 December 2020

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder

1 reference

12 December 2020

The clinical pharmacokinetics of escitalopram

1 reference

12 December 2020

Are SNRIs more effective than SSRIs? A review of the current state of the controversy.

1 reference

12 December 2020

Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial

1 reference

12 December 2020

The pharmacokinetics of escitalopram in patients with hepatic impairment

1 reference

12 December 2020

The burden of recurrent depression: causes, consequences, and future prospects

1 reference

12 December 2020

Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.

1 reference

12 December 2020

Baseline severity of depression predicts antidepressant drug response relative to escitalopram

1 reference

12 December 2020

Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram

1 reference

12 December 2020

Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients

1 reference

12 December 2020

Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder

1 reference

12 December 2020

Escitalopram : a review of its use in the management of major depressive and anxiety disorders

1 reference

12 December 2020

Escitalopram and suicidality in adult depression and anxiety

1 reference

12 December 2020

Blues from the neighborhood? Neighborhood characteristics and depression.

1 reference

12 December 2020

Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany

1 reference

12 December 2020

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

1 reference

12 December 2020

International study on antidepressant prescription pattern at 20 teaching hospitals and major psychiatric institutions in East Asia: Analysis of 1898 cases from China, Japan, Korea, Singapore and Taiwan.

1 reference

12 December 2020

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

1 reference

12 December 2020

Escitalopram: in the treatment of major depressive disorder in adolescent patients

1 reference

12 December 2020

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

1 reference

12 December 2020

Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment.

1 reference

12 December 2020

Escitalopram versus other antidepressive agents for depression

1 reference

12 December 2020

An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder

1 reference

12 December 2020

Escitalopram in the acute treatment of depressed patients aged 60 years or older

1 reference

12 December 2020

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

12 December 2020

Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients

1 reference

12 December 2020

A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

1 reference

12 December 2020

Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data

1 reference

12 December 2020

Efficacy of escitalopram in patients with severe depression: a pooled analysis

1 reference

12 December 2020

Improvements in SSRI/SNRI-induced sexual dysfunction by switching to escitalopram

1 reference

12 December 2020

Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview

1 reference

12 December 2020

Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder

1 reference

12 December 2020

Characterization of an allosteric citalopram-binding site at the serotonin transporter.

1 reference

12 December 2020

Escitalopram causes fewer seizures in human overdose than citalopram.

1 reference

12 December 2020

The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.

1 reference

12 December 2020

Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies

1 reference

12 December 2020

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

12 December 2020

Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder

1 reference

12 December 2020

Escitalopram continuation treatment prevents relapse of depressive episodes

1 reference

12 December 2020

Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.

1 reference

12 December 2020

Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants

1 reference

12 December 2020

Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting

1 reference

12 December 2020

Escitalopram: a review of its use in the management of anxiety disorders

1 reference

12 December 2020

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

1 reference

12 December 2020

Depression as a major component of public health for older adults

1 reference

12 December 2020

Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.

1 reference

12 December 2020

The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation.

1 reference

12 December 2020

Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine

1 reference

12 December 2020

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

12 December 2020

Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique

1 reference

12 December 2020

10.2165/11204760-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

1002828504

0 references

1 reference